Acute interstitial nephritis following treatment with anorectic agents phentermine and phendimetrazine.

Author(s): Markowitz GS, Tartini A, D'Agati VD

Affiliation(s): Department of Pathology, Columbia Presbyterian Medical Center, New York, New York 10032, USA.

Publication date & source: 1998-10, Clin Nephrol., 50(4):252-4.

Publication type: Case Reports

A 47-year-old mildly obese female began a weight reduction program that included anorectic therapy with phentermine and phendimetrazine. A normal urinalysis and serum creatinine were documented at the start of therapy. After three weeks of treatment, the patient felt ill and discontinued her treatment. Subsequently she was found to have leukocyturia, a rash on her face and chest, and a rise in her serum creatinine from 0.8 mg/dl to 2.1 mg/dl. A renal biopsy confirmed the diagnosis of acute interstitial nephritis. The patient was treated with corticosteroids and her renal function returned to normal. Despite the recent withdrawal of two anorectic agents due to data linking them to severe cardiac and pulmonary disease, the appetite suppressants phentermine and phendimetrazine remain in widespread usage for the treatment of obesity. This case represents the first report of acute interstitial nephritis associated with phentermine or phendimetrazine.